Integrated drug formulation and clinical trials company, BDD has secured a further round of investment for £2M to aid the company’s expansion in response to growing demand for both its patented drug delivery technology and specialist clinical trial services.
The funding round was led by existing investors including angel syndicate Archangels, Scottish Enterprise, and new investor British Business Bank.
The latest investment package follows a strong 18 months for the company, which more than doubled revenues in 2022 and has already secured substantial contracts with major pharma and biopharmaceutical companies for 2023 and 2024. This investment will allow the business to increase its clinical capacity and expand capabilities to offer the sector the ease and convenience of a single point of contact for early phase formulation development and clinical evaluation.
- THE EDITORIAL TEAM
- Industry News
- Posted On




